Okayama University Significantly Enhances Anti-Tumor Effects of Hyperthermia with Successful Development of a Novel Sensitizer

Key facts

  • Okayama University Significantly Enhances Anti-Tumor Effects of Hyperthermia with Successful Development of a Novel Sensitizer
  • A research group at Okayama University has successfully developed a new compound that significantly enhances the therapeutic effects of hyperthermia, a type of cancer treatment. This compound inhibits the formation of 'SAFB granules' within the cell nucleus, which are induced by heat stress. In animal experiments, combining this compound with hyperthermia was confirmed to markedly increase anti-tumor effects. This achievement is expected to lead to the development of new, effective cancer drugs (hyperthermia sensitizers) with fewer side effects. The research findings have been published in a U.S. academic journal.
  • Source: PR Times
  • Date: June 1, 2026

Direct answer

A research group at Okayama University has successfully developed a new compound that significantly enhances the therapeutic effects of hyperthermia, a type of cancer treatment. This compound inhibits the formation of 'SAFB granules' within the cell nucleus, which are induced by heat stress. In animal experiments, combining this compound with hyperthermia was confirmed to markedly increase anti-tumor effects. This achievement is expected to lead to the development of new, effective cancer drugs (hyperthermia sensitizers) with fewer side effects. The research findings have been published in a U.S. academic journal.

Citation
Okayama University Significantly Enhances Anti-Tumor Effects of Hyperthermia with Successful Development of a Novel Sensitizer (June 1, 2026), PR Times
Source
PR Times
Date
June 1, 2026
A research group at Okayama University has successfully developed a new compound that significantly enhances the therapeutic effects of hyperthermia, a type of cancer treatment. This compound inhibits the formation of 'SAFB granules' within the cell nucleus, which are induced by heat stress. In animal experiments, combining this compound with hyperthermia was confirmed to markedly increase anti-tumor effects. This achievement is expected to lead to the development of new, effective cancer drugs (hyperthermia sensitizers) with fewer side effects. The research findings have been published in a U.S. academic journal.
healthNQ 47/100出典：PR Times

📋 Article Processing Timeline

  • 📰 Published: June 1, 2026 at 00:39
  • 🔍 Collected: May 31, 2026 at 15:47
  • 🤖 AI Analyzed: June 2, 2026 at 09:19 (41h 31m after Collected)
May 31, 2026 Okayama University - A compound that inhibits the formation of SAFB granules, which are formed by heat stress, has been developed. - In animal experiments, using this compound enhanced the anti-tumor effects of hyperthermia, a cancer treatment method. - Further research and development are expected to lead to the creation of new hyperthermia sensitizers. ◆ Overview A research group from Okayama University's Graduate School of Interdisciplinary Science and Engineering in Health Systems, including graduate students Yuji Furutani, Natsuki Shimasaki, and Riko Yamada, and faculty members Professor Takashi Ohtsuki and Associate Professor Kazunori Watanabe, has developed a compound that inhibits the formation of SAFB granules in the cell nucleus under heat stress. They also demonstrated in animal experiments that combining this compound with hyperthermia, a cancer treatment method, significantly enhances its anti-tumor effects. These research findings were published online in the American international academic journal "Journal of Medicinal Chemistry" on February 18, 2026. Hyperthermia's therapeutic effect is enhanced when used in conjunction with chemotherapy, such as anticancer drugs. However, issues include side effects associated with anticancer drugs and cases where sufficient therapeutic effects are not achieved. The SAFB granule formation inhibitor developed in this study may enhance the effects of hyperthermia through a mechanism different from that of anticancer drugs, and is expected to improve therapeutic outcomes and reduce side effects. Future research and development are anticipated to lead to its application and advancement as a new hyperthermia sensitizer. This matter was publicly released on May 31, 2026. Figure: Inhibition of SAFB granule formation by the SAFB granule formation inhibitor. Immunostaining was performed to stain the nucleus (blue) and SAFB (yellow). The number of SAFB granules (arrows) is lower with the SAFB granule formation inhibitor than with the solvent used to dissolve the inhibitor. ◆ A word from graduate student Yuji Furutani and Associate Professor Kazunori Watanabe This was our first time conducting experiments with tumor-bearing mice, so we were very anxious, but we are extremely pleased that it led to such results. We will use the results of this research as a foundation to aim for further research development and practical application. We also warmly welcome collaborative research. ◆ Publication Information Paper Title: Discovery of thermal sensitizers that inhibit heat-induced SAFB granule formation Journal: Journal of Medicinal Chemistry Authors: Yuji Furutani, Natsuki Shimasaki, Riko Yamada, Takashi Ohtsuki, Kazunori Watanabe DOI: https://doi.org/10.1021/acs.jmedchem.5c03361 URL: https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c03361 ◆ Research Funding This research was conducted with support from the Wesco Scientific Promotion Foundation and the Amano Institute of Technology. The compound library was supported by the Japan Agency for Medical Research and Development (AMED) under the Platform for Drug Discovery, Informatics, and Structural Life Science (BINDS), grant number JP21am0101084. Furthermore, it received APC support from Okayama University for high-impact international academic journals. ◆ For more details on the research Significantly enhancing the anti-tumor effects of hyperthermia - Successful development of a new hyperthermia sensitizer https://www.okayama-u.ac.jp/up_load_files/press_r7/press20260309-1.pdf ◆ References - Okayama University, Institute of Academic and Research Fields, Health System Integration Science, Biomolecular Engineering Laboratory https://www.okayama-u.ac.jp/user/ohtsuki/index.htm - Okayama University, Graduate School of Interdisciplinary Science and Engineering in Health Systems https://www.gisehs.okayama-u.ac.jp/ ◆ Contact for this matter Associate Professor Kazunori Watanabe Institute of Academic and Research Fields, Health System Integration Science, Okayama University 3-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan TEL: +81-86-251-8220 New Medical Research and Development Center, Okayama University Hospital 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan Please use the URL below for relevant inquiries. http://shin-iryo.hospital.okayama-u.ac.jp/ph_company/ Industry-Academia Collaboration Division, Organization for Research and Innovation, Okayama University 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan TEL: +81-86-251-8463 Okayama University, a national university corporation, supports the United Nations' Sustainable Development Goals (SDGs). It was also a recipient of the special award at the first Japan SDGs Awards by the Japanese government. Please look forward to the progress of Okayama University as it promotes co-education and co-creation as a regional core and distinctive research university.

FAQ

How was this research conducted in Okayama?

This research was carried out by a research group based at the Tsushima Campus of Okayama University, a national university corporation located in Kita-ku, Okayama City.

What kind of research support system does Okayama University have?

Okayama University actively supports industry-academia-government collaboration and the practical application of research outcomes through organizations like its Organization for Research and Innovation and the New Medical Research and Development Center.

What economic impact could this achievement have on the Okayama region?

In the future, it could lead to the creation of new pharmaceuticals originating from Okayama, which is expected to vitalize the local pharmaceutical and medical industries and create new employment opportunities.

Back to Newsroom (725)